Aldeyra Therapeutics (ALDX) Current Deferred Revenue (2023 - 2025)
Aldeyra Therapeutics' (ALDX) quarterly Current Deferred Revenue came in at $6.0 million in Q4 2025, little changed YoY from $6.0 million in Q4 2024, and little changed on a QoQ basis from $6.0 million in Q4 2024.
Aldeyra Therapeutics (ALDX) Current Deferred Revenue (2023 - 2025) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 3 years of Current Deferred Revenue data on file, last reported at $6.0 million in Q4 2025.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $6.0 million, changed 0.0% from the prior year.
- Current Deferred Revenue steadied at $6.0 million in Q4 2025, from $6.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $6.0 million in Q4 2023 to a low of $6.0 million in Q4 2023.
- A 3-year average of $6.0 million and a median of $6.0 million in 2023 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 0.0% in 2024, down 0.0% in 2024.
- Tracing ALDX's Current Deferred Revenue over 3 years: stood at $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024, then changed by 0.0% to $6.0 million in 2025.
- The last three Current Deferred Revenue figures came in at $6.0 million (Q4 2025), $6.0 million (Q4 2024), and $6.0 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Sep 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Dec 31, 2023 | 6.00 Mn |